Retraction Note: Jacarelhyperol A induced apoptosis in leukaemia cancer cell through inhibition the activity of Bcl-2 proteins(BMC Cancer, (2014), 14, (689), 10.1186/1471-2407-14-689);Jacarelhyperol A induced apoptosis in leukaemia cancer cell through inhibition the activity of Bcl-2 proteins

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Zhang, Shoude ^a,b   Yin, Jun ^c   Li, Xia ^a   Zhang, Jigang ^a   Yue, Rongcai ^a   Diao, Yanyan ^b   Li, Honglin ^b   Wang, Hui ^c   Shan, Lei ^a   Zhang, Weidong ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Apoptosis; Bcl 2; Hypericum japonicum Thunb.ex Murray; Jacarelhyperol A; Leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CYTOCHROME C; DOXORUBICIN; JACARELHYPEROL A; PLANT MEDICINAL PRODUCT; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG; CASPASE; PROTEIN BCL X; PROTEIN BINDING; XANTHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CONTROLLED STUDY; DIMERIZATION; DOSE RESPONSE; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; HYPERICUM; HYPERICUM JAPONICUM; IC50; K562 CELL LINE; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PROTEIN MULTIMERIZATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BINDING SITES; CASPASES; CELL LINE, TUMOR; CYTOCHROMES C; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; LEUKEMIA; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-BCL-2; XANTHENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908132484     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-022-09868-8     Document Type: Erratum

References (26)

1. Wang XW, Mao Y, Wang NL, Yao XS. A new phloroglucinol diglycoside derivative from Hypericum japonicum Thunb. Molecules 2008, 13(11):2796-2803. 10.3390/molecules13112796, 19002080.
2. Wang N, Li P, Wang Y, Peng W, Wu Z, Tan S, Liang S, Shen X, Su W. Hepatoprotective effect of Hypericum japonicum extract and its fractions. J Ethnopharmacol 2008, 116(1):1-6. 10.1016/j.jep.2007.08.031, 18178045.
3. Zuo GY, An J, Han J, Zhang YL, Wang GC, Hao XY, Bian ZQ. Isojacareubin from the Chinese herb Hypericum japonicum: potent antibacterial and synergistic effects on clinical methicillin-resistant staphylococcus aureus (MRSA). Int J Mol Sci 2012, 13(7):8210-8218. 3430230, 22942699.
4. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999, 13(15):1899-1911. 10.1101/gad.13.15.1899, 10444588.
5. Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, Guo R, Li B, Zhu X, Huang Y, Long YQ, Roller PP, Yang D, Wang S. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001, 44(25):4313-4324. 10.1021/jm010016f, 11728179.
6. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26(9):1324-1337. 10.1038/sj.onc.1210220, 2930981, 17322918.
7. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000, 60(21):6101-6110.
8. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, Cohen GM. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009, 16(7):1030-1039. 10.1038/cdd.2009.48, 19390557.
9. Feng Y, Ding X, Chen T, Chen L, Liu F, Jia X, Luo X, Shen X, Chen K, Jiang H, Wang H, Liu H, Liu D. Design, synthesis, and interaction study of quinazoline-2(1H)-thione derivatives as novel potential Bcl-xL inhibitors. J Med Chem 2010, 53(9):3465-3479. 10.1021/jm901004c, 20405848.
10. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997, 275(5302):983-986. 10.1126/science.275.5302.983, 9020082.
11. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005, 106(4):1154-1163. 10.1182/blood-2005-01-0178, 15870183.
12. Nikolovska-Coleska Z, Wang R, Fang X, Pan H, Tomita Y, Li P, Roller PP, Krajewski K, Saito NG, Stuckey JA, Wang S. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal Biochem 2004, 332(2):261-273. 10.1016/j.ab.2004.05.055, 15325294.
13. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997, 275(5303):1132-1136. 10.1126/science.275.5303.1132, 9027315.
14. Zhang MC, Liu HP, Tian ZK, Griffith BN, Ji M, Li QQ. Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways. Life Sciences 2007, 80(8):767-774. 10.1016/j.lfs.2006.11.004, 17156797.
15. Snowden RT, Sun XM, Dyer MJS, Cohen GM. Bisindolylmaleimide IX is a potent inducer of apoptosis in chronic lymphocytic leukaemic cells and activates cleavage of Mcl-1. Leukemia 2003, 17(10):1981-1989. 10.1038/sj.leu.2403088, 14513048.
16. Dewson G, Snowden RT, Almond JB, Dyer MJS, Cohen GM. Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. Oncogene 2003, 22(17):2643-2654. 10.1038/sj.onc.1206326, 12730678.
17. Ishiguro K, Nagata S, Oku H, Yamaki M. Bisxanthones from Hypericum japonicum: inhibitors of PAF-induced hypotension. Planta Med 2002, 68(3):258-261. 10.1055/s-2002-23125, 11914965.
18. Buolamwini JK. Novel anticancer drug discovery. Curr Opin Chem Biol 1999, 3(4):500-509. 10.1016/S1367-5931(99)80073-8, 10419854.
19. Miao S, Shi X, Zhang H, Wang S, Sun J, Hua W, Miao Q, Zhao Y, Zhang C. Proliferation-attenuating and apoptosis-inducing effects of tryptanthrin on human chronic myeloid leukemia k562 cell line in vitro. Int J Mol Sci 2011, 12(6):3831-3845. 3131594, 21747710.
20. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004, 305(5684):626-629. 10.1126/science.1099320, 15286356.
21. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997, 326(Pt 1):1-16. 1218630, 9337844.
22. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007, 109(12):5430-5438. 10.1182/blood-2006-10-047951, 17332241.
23. Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 2007, 13(7):2226-2235. 10.1158/1078-0432.CCR-06-1574, 17404107.
24. Frame D. New strategies in controlling drug resistance in chronic myeloid leukemia. Am J Health Syst Pharm 2007, 64(24 Suppl 15):S16-S21.
25. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293(5531):876-880. 10.1126/science.1062538, 11423618.
26. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16(11):2190-2196. 10.1038/sj.leu.2402741, 12399961.